Uday Jani, MD
Internal Medicine · Milton, DENPI 1871548693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,637 and has fallen 62.4% since, to $616 in 2025. Among internal medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$590
- Pfizer$482
- Abbott$347
- Amgen$326
- Takeda Pharmaceuticals U.S.A., Inc.$297
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,705100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $1,098 |
| Novo Nordisk | 28 | $590 |
| Pfizer | 26 | $482 |
| Abbott | 6 | $347 |
| Amgen | 7 | $326 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $297 |
| Amarin Pharma, Inc. | 15 | $221 |
| Lilly USA, LLC | 11 | $220 |
| GSK | 6 | $198 |
| AbbVie(2 entities) | 6 | $192 |
| Menarini Silicon Biosystems, Inc. | 2 | $171 |
| Exact Sciences | 6 | $150 |
| Medicure Pharma Inc. | 3 | $144 |
| Astellas Pharma US Inc | 9 | $143 |
| Radius Health, Inc. | 1 | $120 |
| Bausch Health US, LLC | 6 | $117 |
| Currax Pharmaceuticals LLC | 7 | $105 |
| Sanofi | 1 | $102 |
| Boehringer Ingelheim | 2 | $101 |
| Mylan Specialty L.p. | 1 | $78 |
| Intuitive Surgical | 1 | $77 |
| Medtronic | 1 | $77 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Brainsway USA Inc | 1 | $50 |
| Sanofi Pasteur Inc. | 3 | $40 |
| Eisai Inc. | 2 | $38 |
| Grifols USA, LLC | 2 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Novartis | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$467
- Prolia$237
- IMFINZI$150
- SlimTip lead DRG Lead$133
- TRELEGY ELLIPTA$123
- Tymlos$120
- CELLSEARCH$113
- AUBAGIO$102
- Saxenda$101
- PROCLAIM$101
How this compares
$5,719 in reported general payments places this provider in the 90th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $118,694 |
| EliquisApixaban | 60 | $89,234 |
| FarxigaDapagliflozin Propanediol | 46 | $50,185 |
| TrintellixVortioxetine Hydrobromide | 22 | $22,324 |
| XareltoRivaroxaban | 21 | $20,116 |
| MyrbetriqMirabegron | 13 | $15,864 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $12,970 |
| Rosuvastatin Calcium | 255 | $6,692 |
| Atorvastatin Calcium | 240 | $4,422 |
| Dexlansoprazole DrDexlansoprazole | 14 | $4,232 |
| SynthroidLevothyroxine Sodium | 64 | $3,634 |
| Potassium Chloride | 47 | $3,420 |
| Tamsulosin Hcl | 138 | $3,266 |
| Pravastatin Sodium | 93 | $2,685 |
| Losartan Potassium | 196 | $2,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $590 | $118,69457 claims |
| PfizerEliquis, Paxlovid | $482 | $90,66478 claims |
| AstraZenecaFarxiga | $1,098 | $50,18546 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $297 | $22,32422 claims |
| Johnson & JohnsonXarelto | $12 | $20,11621 claims |
| Astellas Pharma US IncMyrbetriq | $143 | $15,86413 claims |
| Esperion Therapeutics, Inc.Nexlizet | $62 | $12,97011 claims |
| AbbVieSynthroid | $192 | $3,63464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Milton
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Bhaskar PalekarLewes$22K
- Fadi DamouniMillsboro$17K
- Rene BadilloBear$16K
- Robert KopeckiWilmington$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.